{"id":"W4393238164","doi":"10.1016/j.kint.2024.03.012","title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","year":2024,"lang":"en","type":"article","venue":"Kidney International","topic":"Renal Diseases and Glomerulopathies","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"BeiGene; International Society of Nephrology; BioCryst; Alnylam Pharmaceuticals; Astellas Pharma; Omeros Corporation; Alexion Pharmaceuticals; AstraZeneca; Argenx; GlaxoSmithKline; Amgen","keywords":"Medicine; Placebo; Double blind; Nephropathy; Randomized controlled trial; Clinical trial; Internal medicine; Endocrinology; Alternative medicine; Diabetes mellitus; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003309295,0.002967695,0.003417424,0.0009491891,0.0007782492,0.00113758,0.001073807,0.002983152,0.009849089],"category_scores_gemma":[0.003046291,0.001072867,0.001395241,0.000587289,0.001278837,0.001387218,0.0004628825,0.003891302,0.002008766],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007376524,"about_ca_system_score_gemma":0.00216321,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006335754,"about_ca_topic_score_gemma":0.001669243,"domain_scores_codex":[0.9988525,0.0005938461,0.00006676597,0.0002140186,0.000122204,0.0001506111],"domain_scores_gemma":[0.9989291,0.0002628243,0.000250123,0.00008810405,0.000117671,0.0003522607],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9499456,0.02060681,0.0004837231,0.0008158706,0.0005315241,0.00005836592,0.00007784747,0.0003457884,0.006161203,0.0002824073,0.002459257,0.01823148],"study_design_scores_gemma":[0.969452,0.02876437,0.0004456139,0.00001753137,0.00007813283,0.00002251573,0.000005836564,0.0002342931,0.0002362142,0.00009311486,0.0006418789,0.000008431402],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9225181,0.008248211,0.004023794,0.002337171,0.002091866,0.04817211,0.005180425,0.0007798033,0.006648483],"genre_scores_gemma":[0.8872311,0.006795688,0.01447056,0.005288935,0.00165154,0.06490703,0.006342949,0.000148169,0.01316393],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009849089,"threshold_uncertainty_score":0.03294855,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06695141830526719,"score_gpt":0.4256853226899625,"score_spread":0.3587339043846953,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}